Abstract |
TSC-mutated sarcomas are rare molecular and histologic types of sarcoma. Due to the presence of their specific oncogenic driver mutation, these sarcomas are particularly sensitive to mTOR inhibitors. Recently, nab- sirolimus, an albumin-bound mTOR inhibitor, was approved by the Food and Drug Administration (FDA) for PEComas, which harbor a TSC mutation, and this drug remains the only FDA-approved systemic treatment for these tumors. We report on two cases of patients with TSC-mutated sarcomas who experienced significant responses to the combination of gemcitabine and sirolimus, after progression on prior gemcitabine-based chemotherapy and single agent mTOR inhibition with nab- sirolimus. Preclinical and clinical data support rationale for a synergistic effect of the combination. This combination may represent a valid therapeutic option after failure of nab- sirolimus in these patients, with no standard-of-care treatment options.
|
Authors | Elise F Nassif, Cissimol P Joseph, Rossana Lazcano, Jocelyn T Joseph, Prapassorn Thirasastr, Alexander J Lazar, Neeta Somaiah |
Journal | Frontiers in oncology
(Front Oncol)
Vol. 13
Pg. 1046442
( 2023)
ISSN: 2234-943X [Print] Switzerland |
PMID | 36845725
(Publication Type: Case Reports)
|
Copyright | Copyright © 2023 Nassif, Joseph, Lazcano, Joseph, Thirasastr, Lazar and Somaiah. |